九州大学 · Medicine
이 교수의 연구실은 대장암을 비롯한 소장암의 분자생물학적 기반을 규명하고, 종양 내 이질성과 치료 내성 메커니즘을 해소하기 위한 정밀의료 전략을 개발하고 있습니다. 특히 수술 후 혈액 내 종양 DNA(ctDNA) 분석을 통한 재발 위험 예측 및 치료 결정 지원 시스템의 임상적 적용을 중심으로 연구를 진행하고 있으며, AKT/PI3K 경로를 통한 내성 기전 규명도 핵심 과제입니다. 장기적으로는 종양의 진화적 역사 분석과 유전체·에피유전체 다중 분석을 통해 개인 맞춤 치료 전략을 제안하고자 합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II-IV resectable CRC (n = 1,039). In this cohort, with a medi
Growth factor receptor-mediated signal transduction has been implicated in conferring resistance to conventional chemotherapy on cancer cells. We describe a pathway that involves AKT/PI3K to mediate chemoresistance in gastric cancer patients. Primary gastric carcinoma tissues and corresponding normal mucosa were obtained from 76 gastric cancer patients who underwent surgery in the Department of Surgery II in Kyushu University Hospital from the years 1996-2000. AKT activation was investigated by
Understanding intratumor heterogeneity is clinically important because it could cause therapeutic failure by fostering evolutionary adaptation. To this end, we profiled the genome and epigenome in multiple regions within each of nine colorectal tumors. Extensive intertumor heterogeneity is observed, from which we inferred the evolutionary history of the tumors. First, clonally shared alterations appeared, in which C>T transitions at CpG site and CpG island hypermethylation were relatively enrich
